SYNEOS HEALTH INC (SYNH) Stock Fundamental Analysis
USA - NASDAQ:SYNH - US87166B1026 - Common Stock
42.98 USD
+0.01 (+0.02%)
42.97 USD
-0.01 (-0.02%)
Overall SYNH gets a fundamental rating of 4 out of 10. We evaluated SYNH against 58 industry peers in the Life Sciences Tools & Services industry. There are concerns on the financial health of SYNH while its profitability can be described as average. A decent growth rate in combination with a cheap valuation! Better keep an eye on SYNH.
1. Profitability
1.1 Basic Checks
SYNH had positive earnings in the past year.
In the past year SYNH had a positive cash flow from operations.
In the past 5 years SYNH has always been profitable.
In the past 5 years SYNH always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of SYNH (0.88%) is better than 70.31% of its industry peers.
SYNH has a Return On Equity of 2.04%. This is in the better half of the industry: SYNH outperforms 71.88% of its industry peers.
SYNH has a better Return On Invested Capital (4.23%) than 70.31% of its industry peers.
SYNH had an Average Return On Invested Capital over the past 3 years of 4.99%. This is significantly below the industry average of 13.56%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.88% | ||
| ROE | 2.04% | ||
| ROIC | 4.23% |
ROA(3y)2.83%
ROA(5y)2.12%
ROE(3y)6.82%
ROE(5y)5.13%
ROIC(3y)4.99%
ROIC(5y)4.67%
1.3 Margins
SYNH has a better Profit Margin (1.31%) than 70.31% of its industry peers.
In the last couple of years the Profit Margin of SYNH has grown nicely.
SYNH has a better Operating Margin (6.33%) than 65.63% of its industry peers.
SYNH's Operating Margin has improved in the last couple of years.
SYNH's Gross Margin of 22.14% is on the low side compared to the rest of the industry. SYNH is outperformed by 84.38% of its industry peers.
SYNH's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.33% | ||
| PM (TTM) | 1.31% | ||
| GM | 22.14% |
OM growth 3Y5.34%
OM growth 5Y13.1%
PM growth 3Y20.73%
PM growth 5YN/A
GM growth 3Y1.57%
GM growth 5Y0.02%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SYNH is destroying value.
SYNH has less shares outstanding than it did 1 year ago.
Compared to 1 year ago, SYNH has an improved debt to assets ratio.
2.2 Solvency
SYNH has an Altman-Z score of 1.46. This is a bad value and indicates that SYNH is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.46, SYNH perfoms like the industry average, outperforming 43.75% of the companies in the same industry.
SYNH has a debt to FCF ratio of 16.71. This is a negative value and a sign of low solvency as SYNH would need 16.71 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 16.71, SYNH is doing good in the industry, outperforming 65.63% of the companies in the same industry.
SYNH has a Debt/Equity ratio of 0.77. This is a neutral value indicating SYNH is somewhat dependend on debt financing.
SYNH's Debt to Equity ratio of 0.77 is on the low side compared to the rest of the industry. SYNH is outperformed by 79.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 16.71 | ||
| Altman-Z | 1.46 |
ROIC/WACC0.39
WACC10.92%
2.3 Liquidity
A Current Ratio of 1.20 indicates that SYNH should not have too much problems paying its short term obligations.
SYNH has a worse Current ratio (1.20) than 93.75% of its industry peers.
A Quick Ratio of 1.20 indicates that SYNH should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.20, SYNH is doing worse than 82.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.2 | ||
| Quick Ratio | 1.2 |
3. Growth
3.1 Past
SYNH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -23.79%.
Measured over the past years, SYNH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.74% on average per year.
The Revenue has been growing slightly by 0.01% in the past year.
The Revenue has been growing by 15.08% on average over the past years. This is quite good.
EPS 1Y (TTM)-23.79%
EPS 3Y13.48%
EPS 5Y13.74%
EPS Q2Q%-54.4%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y4.87%
Revenue growth 5Y15.08%
Sales Q2Q%0.39%
3.2 Future
Based on estimates for the next years, SYNH will show a small growth in Earnings Per Share. The EPS will grow by 3.17% on average per year.
Based on estimates for the next years, SYNH will show a small growth in Revenue. The Revenue will grow by 1.71% on average per year.
EPS Next Y-25.43%
EPS Next 2Y-6.79%
EPS Next 3Y-1.2%
EPS Next 5Y3.17%
Revenue Next Year-2.82%
Revenue Next 2Y-0.54%
Revenue Next 3Y1.03%
Revenue Next 5Y1.71%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 11.37, the valuation of SYNH can be described as very reasonable.
100.00% of the companies in the same industry are more expensive than SYNH, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 25.51, SYNH is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 10.48, the valuation of SYNH can be described as reasonable.
100.00% of the companies in the same industry are more expensive than SYNH, based on the Price/Forward Earnings ratio.
SYNH's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.98.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.37 | ||
| Fwd PE | 10.48 |
4.2 Price Multiples
SYNH's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SYNH is cheaper than 95.31% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SYNH indicates a rather cheap valuation: SYNH is cheaper than 85.94% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.53 | ||
| EV/EBITDA | 12.05 |
4.3 Compensation for Growth
SYNH has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.83
EPS Next 2Y-6.79%
EPS Next 3Y-1.2%
5. Dividend
5.1 Amount
No dividends for SYNH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
42.98
+0.01 (+0.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner Change0%
Ins Owners0.49%
Ins Owner Change0%
Market Cap4.46B
Revenue(TTM)5.42B
Net Income(TTM)71.22M
Analysts53.75
Price Target43.35 (0.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.02%
Min EPS beat(2)-29.57%
Max EPS beat(2)11.52%
EPS beat(4)2
Avg EPS beat(4)-6.43%
Min EPS beat(4)-29.57%
Max EPS beat(4)11.52%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.57%
Min Revenue beat(2)3.81%
Max Revenue beat(2)5.33%
Revenue beat(4)3
Avg Revenue beat(4)1.96%
Min Revenue beat(4)-4.69%
Max Revenue beat(4)5.33%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.13%
EPS NQ rev (1m)-1.52%
EPS NQ rev (3m)0.41%
EPS NY rev (1m)1.03%
EPS NY rev (3m)4.38%
Revenue NQ rev (1m)0.31%
Revenue NQ rev (3m)1.89%
Revenue NY rev (1m)0.55%
Revenue NY rev (3m)2.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.37 | ||
| Fwd PE | 10.48 | ||
| P/S | 0.82 | ||
| P/FCF | 27.53 | ||
| P/OCF | 17.62 | ||
| P/B | 1.28 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.05 |
EPS(TTM)3.78
EY8.79%
EPS(NY)4.1
Fwd EY9.54%
FCF(TTM)1.56
FCFY3.63%
OCF(TTM)2.44
OCFY5.67%
SpS52.25
BVpS33.68
TBVpS-19.54
PEG (NY)N/A
PEG (5Y)0.83
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.88% | ||
| ROE | 2.04% | ||
| ROCE | 5.32% | ||
| ROIC | 4.23% | ||
| ROICexc | 4.29% | ||
| ROICexgc | 32.26% | ||
| OM | 6.33% | ||
| PM (TTM) | 1.31% | ||
| GM | 22.14% | ||
| FCFM | 2.99% |
ROA(3y)2.83%
ROA(5y)2.12%
ROE(3y)6.82%
ROE(5y)5.13%
ROIC(3y)4.99%
ROIC(5y)4.67%
ROICexc(3y)5.11%
ROICexc(5y)4.79%
ROICexgc(3y)50.55%
ROICexgc(5y)76.43%
ROCE(3y)6.27%
ROCE(5y)5.87%
ROICexgc growth 3Y-8.19%
ROICexgc growth 5Y1.51%
ROICexc growth 3Y6.95%
ROICexc growth 5Y27.79%
OM growth 3Y5.34%
OM growth 5Y13.1%
PM growth 3Y20.73%
PM growth 5YN/A
GM growth 3Y1.57%
GM growth 5Y0.02%
F-Score6
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 16.71 | ||
| Debt/EBITDA | 4.56 | ||
| Cap/Depr | 37.2% | ||
| Cap/Sales | 1.68% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 43.05% | ||
| Profit Quality | 227.34% | ||
| Current Ratio | 1.2 | ||
| Quick Ratio | 1.2 | ||
| Altman-Z | 1.46 |
F-Score6
WACC10.92%
ROIC/WACC0.39
Cap/Depr(3y)28.14%
Cap/Depr(5y)26.15%
Cap/Sales(3y)1.32%
Cap/Sales(5y)1.31%
Profit Quality(3y)162.48%
Profit Quality(5y)341.03%
High Growth Momentum
Growth
EPS 1Y (TTM)-23.79%
EPS 3Y13.48%
EPS 5Y13.74%
EPS Q2Q%-54.4%
EPS Next Y-25.43%
EPS Next 2Y-6.79%
EPS Next 3Y-1.2%
EPS Next 5Y3.17%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y4.87%
Revenue growth 5Y15.08%
Sales Q2Q%0.39%
Revenue Next Year-2.82%
Revenue Next 2Y-0.54%
Revenue Next 3Y1.03%
Revenue Next 5Y1.71%
EBIT growth 1Y-27.25%
EBIT growth 3Y10.47%
EBIT growth 5Y30.16%
EBIT Next Year-2.87%
EBIT Next 3Y4.37%
EBIT Next 5Y3.5%
FCF growth 1Y-63.52%
FCF growth 3Y9.43%
FCF growth 5Y16.65%
OCF growth 1Y-47.97%
OCF growth 3Y10.26%
OCF growth 5Y16.58%
SYNEOS HEALTH INC / SYNH FAQ
What is the ChartMill fundamental rating of SYNEOS HEALTH INC (SYNH) stock?
ChartMill assigns a fundamental rating of 5 / 10 to SYNH.
Can you provide the valuation status for SYNEOS HEALTH INC?
ChartMill assigns a valuation rating of 7 / 10 to SYNEOS HEALTH INC (SYNH). This can be considered as Undervalued.
Can you provide the profitability details for SYNEOS HEALTH INC?
SYNEOS HEALTH INC (SYNH) has a profitability rating of 6 / 10.
What is the valuation of SYNEOS HEALTH INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for SYNEOS HEALTH INC (SYNH) is 11.37 and the Price/Book (PB) ratio is 1.28.
What is the earnings growth outlook for SYNEOS HEALTH INC?
The Earnings per Share (EPS) of SYNEOS HEALTH INC (SYNH) is expected to decline by -25.43% in the next year.